Wednesday, Feb. 24, 2027
9 a.m.–1 p.m. Registration
1–1:05 p.m. Opening Remarks
Keynote Address
1:05–1:55 p.m.
Session I: Next-gen CAR T: Genetic Engineering to Optimize T cell Fitness While Minimizing Toxicity
1:55–3:15 p.m.
1:55–2:15 p.m. Kole T. Roybal, PhD — University of California, San Francisco
2:15–2:35 p.m. Priti Hegde, PhD — Kite Pharma, Inc.
2:35–2:55 p.m. Gordon Moody, MS — AstraZeneca
2:55–3:05 p.m. Abstract Presentation
3:05–3:15 p.m. Abstract Presentation
3:15–3:40 p.m. Break
Session II: Next-gen TILs
3:40–5 p.m.
3:40–4 p.m. Parameswaran Hari, MD — Obsidian Therapeutics
4–4:20 p.m. George Coukos, MD, PhD, FAIO — Weill Cornell Medicine
4:20–4:40 p.m. TIL Therapy as a Front-line Therapy for Advanced Solid Tumors
Brian R. Gastman, MD — Iovance Biotherapeutics
4:40–4:50 p.m. Abstract Presentation
4:50–5 p.m. Abstract Presentation
5–6:30 p.m. Poster Session and Networking Reception
Thursday, Feb. 25, 2027
7:30–8:30 a.m. Registration
8:30–8:35 a.m. Opening Remarks
Session III: Next-gen TCR T Cells and TCR Mimetics
8:35–9:55 a.m.
8:35–8:55 a.m. Mark Yarmarkovich, PhD — NYU Grossman School of Medicine
8:55–9:15 a.m. Christopher A. Klebanoff, MD — Memorial Sloan Kettering Cancer Center
9:15–9:35 a.m. Delfi Krishna, PhD — Immatics Biotechnologies
9:35–9:45 a.m. Abstract Presentation
9:45–9:55 a.m. Abstract Presentation
9:55–10:20 a.m. Break
Session IV: In vivo Cell Therapies — Viral
10:20–11:50 a.m.
10:20–10:40 a.m. Deepti Telaraja, MD — Lilly
10:40–11 a.m.
11–11:20 a.m. Dian Kortleve, PhD — University of California, San Francisco
11:20–11:40 a.m. Jennifer Hamilton, PhD — Azalea Therapeutics
11:40–11:50 a.m. Abstract Presentation
11:50 a.m.–1 p.m. Lunch and Networking
Session V: In vivo Cell Therapies — Non-viral
1–2:40 p.m.
1–1:20 p.m. Luhan Yang, PhD — Qihan Biotech
1:20–1:40 p.m. Non-viral Integrative Technology for CAR T cells
Cecilia Cotta-Ramusino — Tessera Therapeutics
1:40–2 p.m.
Targeting Strategies, microRNA-based Targeting
Brian Brown, PhD — Icahn School of Medicine at Mount Sinai
2–2:20 p.m.
2:20–2:30 p.m. Abstract Presentation
2:30–2:40 p.m. Abstract Presentation
2:40–3:05 p.m. Break
Session VI: Cell Therapy for Non-oncology Indications and Autoimmunity
3:05–4:15 p.m.
3:05–3:25 p.m. Ashley K. Koegel, MD — Bristol Myers Squibb
3:25–3:45 p.m. Justin Eyquem, PhD — University of California, San Francisco
3:45–4:05 p.m. Gwendolyn Binder, PhD — Cabaletta Bio
4:05–4:15 p.m. Abstract Presentation
4:15–6 p.m. Poster Session and Networking Reception
Friday, Feb. 26, 2027
7:30–8:30 a.m. Registration
8:30–8:35 a.m. Opening Remarks
Session VII: Novel Antibody-based Therapies
8:35–10:05 a.m.
8:35–8:55 a.m. PD-1 + ADC
Gary C. Starling, PhD — Astellas
8:55–9:15 a.m.
9:15–9:35 a.m.
9:35–9:55 a.m.
9:55–10:05 a.m. Abstract Presentation
10:05–10:30 a.m. Break
Session VIII: Next-gen T cell Engagers
10:30–11:50 a.m.
10:30–10:50 a.m. Olivier Nolan-Stevaux, PhD — Gilead Sciences, Inc.
10:50–11:10 a.m. Ensar Halilovic, PhD — Crossbow Therapeutics
11:10–11:30 a.m.
11:30–11:40 a.m. Abstract Presentation
11:40–11:50 a.m. Abstract Presentation
11:50 a.m.–1 p.m. Lunch and Networking
Session IX: Cancer Vaccines
1–2:10 p.m. Moderator: Darrell J. Irvine, PhD — The Scripps Research Institute
1–1:20 p.m.KRAS Vaccine for Pancreatic Cancer
Neeha Zaidi, MD — Johns Hopkins Medicine
1:20–1:40 p.m. David M. Berman, MD, PhD — Moderna
1:40–2 p.m.
2–2:10 p.m. Abstract Presentation
2:10–2:25 p.m. Break
Session X: Oncolytic Viruses and other In vivo Tumor Delivery Systems
2:25–3:40 p.m.
2:25–2:45 p.m. CAR T + oncolytic virus
Barbra J. Sasu, PhD — Dispatch Biotherapeutics
2:45–3:05 p.m. GM-CSF armed adenovirus
Vijay Kasturi, MD — CG Oncology
3:05–3:25 p.m.Bringing In Vivo CAR-T to Solid Tumors
Matthias Stephan, MD, PhD — Fred Hutchinson Cancer Research Center
3:25–3:35 p.m. Abstract Presentation
3:35–3:40 p.m. Closing Remarks